Asia Pacific Antibody Drug Conjugates Market Growth, Size, Share, Trends, Key Players Analysis, and Forecast till 2031

The Asia Pacific Antibody Drug Conjugates Market size is expected to reach US$ 6,769.7 Million by 2031 from US$ 1,357.8 Million in 2023. The market is estimated to record a CAGR of 22.2% from 2023 to 2031.

Executive Summary and Asia Pacific Antibody Drug Conjugates Market Analysis:

The Asia Pacific antibody drug conjugates market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The Asia-Pacific antibody-drug conjugates (ADC) market is primarily driven by the increase in cancer cases, alongside rising investments in ADC research and technology. Innovations in linker technologies and cytotoxic agents have improved the efficacy and safety of ADCs. Furthermore, favorable regulatory frameworks in countries like Japan have supported ADC development. The market is highly competitive, with major global players such as Pfizer, AstraZeneca, and Roche taking the lead. Emerging biotech firms like HaemaLogiX and BioNTech are also making significant advancements, increasing competition. Collaborations, including partnerships by Ono Pharmaceutical and growing support for local biotech innovation, further intensify rivalry in the market.

Asia Pacific Antibody Drug Conjugates Market: Strategic Insights

Asia Pacific Antibody Drug Conjugates Market Segmentation Analysis:

• By Technology, the Asia Pacific Antibody Drug Conjugates Market is segmented into Cleavable Linker and Non-cleavable Linker. Cleavable Linker held the largest share of the market in 2023.
• By Application, the Asia Pacific Antibody Drug Conjugates Market is segmented into Blood Cancer, Brain Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, and Others. Breast Cancer held the largest share of the market in 2023.
• By Target, the Asia Pacific Antibody Drug Conjugates Market is segmented into HER2, CD22, CD30, and Others. HER2 held the largest share of the market in 2023.
• By Distribution Channel, the Asia Pacific Antibody Drug Conjugates Market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Hospital Pharmacies held the largest share of the market in 2023.

Asia Pacific Antibody Drug Conjugates Market Players Density: Understanding Its Impact on Business Dynamics

The Asia Pacific Antibody Drug Conjugates Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Asia Pacific Antibody Drug Conjugates Market Outlook

The expansion into new indications is creating significant opportunities in the antibody-drug conjugates market. As antibody-drug conjugates are primarily designed to deliver cytotoxic agents directly to cancer cells while sparing healthy tissues, their ability to target specific tumor-associated antigens makes them highly versatile. This versatility allows for exploring antibody-drug conjugate applications beyond their initial indications, i.e., hematological malignancies and certain solid tumors. Many cancers currently lack adequate treatment options, and introducing antibody-drug conjugates targeting new biomarkers can provide innovative therapies for these challenging conditions. For instance, antibody-drug conjugates are being investigated for treating cancers such as breast, lung, and bladder cancers, where traditional therapies may not yield satisfactory results.

Additionally, the collaboration between pharmaceutical companies and research institutions fosters innovation in antibody-drug conjugate development. These partnerships often focus on identifying novel targets and optimizing linker technologies to enhance the efficacy and safety profiles of conjugates. Moreover, with the discovery and validation of new targets, antibody-drug conjugates are being further investigated for their potential utilization in the treatment of a broader range of cancer types. In June 2024, ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the development of innovative biopharmaceutical therapeutics, entered into a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd., a wholly owned subsidiary of Alphamab Oncology, to discover, develop, and commercialize novel antibody-drug conjugates for the treatment of cancers. By addressing unmet medical needs, benefiting from favorable regulatory conditions, capitalizing on the rising prevalence of cancer, and fostering collaborative innovation, antibody-drug conjugates are poised to play a pivotal role in the future of targeted cancer therapies. Thus, an expansion into new indications presents a wealth of opportunities for the antibody-drug conjugates market.

Asia Pacific Antibody Drug Conjugates Market Country Insights

By country, the Asia Pacific Antibody Drug Conjugates Market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. Japan held the largest share in 2023.

Regulations for biopharmaceutical products in Japan vary significantly from those of the US FDA and the European Commission. In September 2021, Astellas Pharma Inc. and Seagen Inc. (acquired by Pfizer, Inc.) received approval from the Ministry of Health, Labour and Welfare (MHLW) of Japan for its PADCEV (enfortumab vedotin) antibody-drug conjugate. The product is intended to treat relapsed, radically unresectable urothelial cancer after receiving anti-cancer chemotherapy. The approval is based on the positive outcomes of the global Phase 3 EV-301 clinical trial in Japan. Some Japanese companies are also introducing breakthrough products that are expected to dominate the antibody-drug conjugates market. In June 2021, Eisai Co., Ltd. and Bristol-Myers Squibb Company entered into an exclusive global collaboration agreement for the joint development and commercialization of MORAb-202, Eisai's first antibody-drug conjugate. MORAb-202 is being investigated in patients with folate receptor alpha (FRα)-positive solid tumors, including endometrial, ovarian, lung, and breast cancers, through a Phase 1 study in Japan. In August 2023, ImmunoGen, Inc. and Takeda Pharmaceutical Company Limited collaborated to develop and commercialize ELAHERE, ImmunoGen's antibody-drug conjugate therapy, in Japan. Under the collaboration agreement, ImmunoGen, Inc. received upfront and additional payments upon conversion of ELAHERE's accelerated approval by FDA in platinum-resistant ovarian cancer (PROC) to full approval. Under this arrangement, Takeda would pay an additional payment to ImmunoGen, Inc. upon achieving certain regulatory and commercial milestones, and double-digit royalties through the net sales of ELAHERE in Japan. Nevertheless, Immunogen has retained its exclusive production rights and will supply the product for development and commercialization in Japan. Takeda is also responsible for all regulatory filings and will have an exclusive license to develop and commercialize ELAHERE in Japan.

Asia Pacific Antibody Drug Conjugates Market Company Profiles

Some of the key players operating in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, Gilead Sciences Inc, BioNTech SE, Daiichi Sankyo Co Ltd, RemeGen Co Ltd, and ADC Therapeutics SA.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Asia Pacific Antibody Drug Conjugates Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise